Skip to main content

Students in leadership positions learn about brain tumors and gain real world experience in running a non-profit business while raising funds for brain tumor research. Beneficiaries of the money we raise are Barrow Neurological Institute, National Brain Tumor Society, Phoenix Children's Hospital, Translational Genomics Research Institute, and University of Arizona.

"Be the change you wish to see in the world..." Gandhi

Our Beneficiaries

  • University of AZ Research Centers
    University of AZ Research Centers
  • Quote 6 - Erich Fromm

    “Not he who has much is rich but he who gives much.”

    — Erich Fromm

Brain Tumor Research News

An international research group has investigated the mechanisms of cell migration and the impact of tissue rigidity on cell positioning and steering. The research sheds light on e.g. cancer cell migration and opens new possibilities for stopping and directing it.

Today, the National Comprehensive Cancer Network® (NCCN®) published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pediatric Central Nervous System (CNS) Cancers. This is now the fifth current NCCN Guidelines® to focus on childrens’ cancers, following recent publications of evidence-based, expert consensus guidelines for Pediatric Acute Lymphoblastic Leukemia, Pediatric Aggressive Mature B-Cell Lymphomas, Pediatric Hodgkin Lymphoma, and Wilms Tumors. Though rare, pediatric brain tumors are the second-most-common type of pediatric malignancy after leukemia and are the leading cause of cancer-related death in children.

Brad Pitt arrives at the 2020 Oscars at the Dolby Theatre in Los Angeles. Photo: The Associated Press
By News@TheU
07-08-2022
Prosopagnosia, an ailment that made headlines this week after actor Brad Pitt announced that he is suffering from the disorder, is an uncommon brain malady that causes the inability to recognize faces.

Tumors are made up of many types of cells, both cancerous and benign. The specific complexity of the cells inside brain tumors has been a trademark of the disease, one that makes treatment extremely difficult. While scientists have long known about the variety of cells within a brain tumor, the ways these tumors grow has relied on the understanding that the cells are static, unmoving and relatively fixed.

The classification of brain tumors – and thus the choice of optimal treatment options – can become more accurate and precise through the use of artificial intelligence in combination with physiological imaging. This is the result of an extensive study conducted by the Karl Landsteiner University for Health Sciences (KL Krems). Multiclass machine learning methods were used to analyze and classify brain tumors using physiological data from magnetic resonance imaging.

The FDA has granted an orphan drug designation (ODD) to paxalisib (GDC-0084), for the treatment of patients with atypical rhabdoid or teratoid tumors (AT/RT) in rare and aggressive childhood brain cancer, according to Kazia Therapeutics Limited.1

View Previous News Articles - Click Here!